BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Trastuzumab Emtansine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Trastuzumab Emtansine\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05323955-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT05323955)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, Breast Cancer.\nStudy: Second
 ary BRain Metastases Prevention After Isolated Intracranial Progression on
  Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal
  Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib\nE
 stimated primary completion: November 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05323955
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673029-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270109
DTEND;VALUE=DATE:20270110
SUMMARY:Trastuzumab Emtansine: Phase 3 readout est. (NCT07673029)
DESCRIPTION:Trastuzumab Emtansine\, phase 3\, HER2-Positive Breast Cancer.\
 nStudy: A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive 
 Unresectable or Metastatic Breast Cancer\nEstimated primary completion: 9 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuz
 umab-emtansine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07673029
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04733118-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT04733118)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, Breast Cancer.\nStudy: Chemot
 herapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in H
 ER2-positive Early Breast Cancer\nEstimated primary completion: March 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-emtansi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4733118
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05673928-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT05673928)
DESCRIPTION:Trastuzumab Emtansine\, phase 2.\nStudy: A Phase II Study of Tu
 catinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positi
 ve Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)\nEstimated 
 primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/trastuzumab-emtansine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05673928
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00781612-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT00781612)
DESCRIPTION:Trastuzumab Emtansine\, phase 2.\nStudy: A Safety Extension Stu
 dy of Trastuzumab Emtansine in Participants Previously Treated With Trastu
 zumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in 
 One of the Parent Studies\nEstimated primary completion: 30 June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-emtansine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT007816
 12
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04301375-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT04301375)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Omission of Surgery and Sentinel Lymph Node Dissection in Clinical
 ly Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Comp
 lete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELP
 IS Trial)\nEstimated primary completion: 15 July 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04301375
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05081609-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Trastuzumab Emtansine: Phase 1/2 readout est. (NCT05081609)
DESCRIPTION:Trastuzumab Emtansine\, phase 1/2\, Breast Cancer.\nStudy: A St
 udy to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or
  in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other
  Anticancer Therapies in Adult Participants With Locally Advanced or Metas
 tatic Solid Tumor Malignancies\nEstimated primary completion: August 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-emtansin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 081609
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05593094-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Trastuzumab Emtansine: Phase 1/2 readout est. (NCT05593094)
DESCRIPTION:Trastuzumab Emtansine\, phase 1/2\, HER2-Positive Breast Cancer
 .\nStudy: A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in 
 Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
  Advanced Solid Tumors\nEstimated primary completion: 31 August 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-emtansine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0559309
 4
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825753-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT07825753)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, Breast Cancer.\nStudy: Protei
 n-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Canc
 er\nEstimated primary completion: 1 September 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07825753
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04266249-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT04266249)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, Breast Cancer.\nStudy: Compas
 sHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-su
 rgery Chemo and Targeted Therapy\nEstimated primary completion: 31 October
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-em
 tansine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04266249
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07198672-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Trastuzumab Emtansine: Phase na readout est. (NCT07198672)
DESCRIPTION:Trastuzumab Emtansine\, phase na\, HER2-Positive Breast Cancer.
 \nStudy: Primary Prevention of Thrombocytopenia Associated With T-DM1 Ther
 apy in HER2 Positive Breast Cancer With Herombopag\nEstimated primary comp
 letion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/trastuzumab-emtansine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07198672
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Trastuzumab Emtansine\, phase 2.\nStudy: Targeted Therapy Direc
 ted by Genetic Testing in Treating Patients With Advanced Refractory Solid
  Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04620187-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT04620187)
DESCRIPTION:Trastuzumab Emtansine\, phase 2.\nStudy: Post-op T-DM1 in HER-2
 + Salivary Gland Carcinomas\nEstimated primary completion: 1 February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-emtansi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4620187
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT04931342)
DESCRIPTION:Trastuzumab Emtansine\, phase 2.\nStudy: A Study Evaluating the
  Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persis
 tent or Recurrent Rare Epithelial Ovarian Tumors\nEstimated primary comple
 tion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/trastuzumab-emtansine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04931342
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05408845-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT05408845)
DESCRIPTION:Trastuzumab Emtansine\, phase 2.\nStudy: Testing the Use of Ado
 -Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With 
 Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent\, Meta
 static\, or Unresectable HER2-Expressing Salivary Gland Cancers\nEstimated
  primary completion: 31 July 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/trastuzumab-emtansine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05408845
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04893109-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT04893109)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: ATEMPT 2.0: Adjuvant T-DM1 vs TH\nEstimated primary completion: 1 
 November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastu
 zumab-emtansine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04893109
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05288777-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab Emtansine: Phase 2/3 readout est. (NCT05288777)
DESCRIPTION:Trastuzumab Emtansine\, phase 2/3\, Breast Cancer.\nStudy: Adju
 vant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer\
 nEstimated primary completion: December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05288777
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06324357-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Trastuzumab Emtansine: Phase 1/2 readout est. (NCT06324357)
DESCRIPTION:Trastuzumab Emtansine\, phase 1/2\, Breast Cancer.\nStudy: Beam
 ion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and 
 in Combination With Other Treatments to Test Whether it Helps People With 
 Different Types of HER2+ Cancer That Has Spread\nEstimated primary complet
 ion: 8 January 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 trastuzumab-emtansine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06324357
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04341181-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT04341181)
DESCRIPTION:Trastuzumab Emtansine\, phase 2.\nStudy: ProTarget - A Danish N
 ationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Pro
 filing\nEstimated primary completion: 30 April 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04341181
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439693-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20300330
DTEND;VALUE=DATE:20300331
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT06439693)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: The SAPPHO Study: Sequential Therapy With Curative Intent in de No
 vo HER2+ Metastatic Breast Cancer\nEstimated primary completion: 30 March 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-emt
 ansine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06439693
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to
  Treat Breast Cancer\nEstimated primary completion: December 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-emtansine#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578116-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Trastuzumab Emtansine: Phase 3 readout est. (NCT07578116)
DESCRIPTION:Trastuzumab Emtansine\, phase 3\, HER2-Positive Breast Cancer.\
 nStudy: Adding Surgery and Radiation to the Usual Treatment for HER2-Posit
 ive Breast Cancer That Had Already Spread at Diagnosis\nEstimated primary 
 completion: 31 May 2032. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/trastuzumab-emtansine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07578116
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04589845-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20320925
DTEND;VALUE=DATE:20320926
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT04589845)
DESCRIPTION:Trastuzumab Emtansine\, phase 2.\nStudy: Tumor-agnostic Precisi
 on Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platf
 orm Study\nEstimated primary completion: 25 September 2032. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04589845
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06348134-2244@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20340701
DTEND;VALUE=DATE:20340702
SUMMARY:Trastuzumab Emtansine: Phase 2 readout est. (NCT06348134)
DESCRIPTION:Trastuzumab Emtansine\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian
  Women With HER2+ Breast Cancer Before and After Surgery\nEstimated primar
 y completion: 1 July 2034. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/trastuzumab-emtansine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06348134
URL:https://assetmemo.bio/drug/trastuzumab-emtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
